Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...

CSL Ltd (ASX: CSL) shares were sold off in 2025. Let's find out why and see if this is a buying opportunity for ...

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post ...

Narrow-moat CSL reported fiscal 2024 revenue of USD 14.8 billion and net profit after tax before amortization of USD 2.9 billion, up 11% and 15% in constant currency, respectively, close to our ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

Good morning, everyone, and welcome to CSL's Financial Year 2024 Results Presentation. I'm Joy Linton, CSL's Chief Financial Officer. And before we begin the formalities today, I would like to say a ...

CSLLY's FY 2024 results were good thanks to the outperformance of the Behring segment; the company's net profit in constant currency terms grew +15% YoY to $2.91 billion, which was in line with ...